



World Health
Organization

Non-specific effects of BCG, DTP and MV vaccines on child mortality

Terry Nolan

Scientific Advisory Group of Experts (SAGE)

and University of Melbourne



MELBOURNE SCHOOL OF
POPULATION
& GLOBAL
HEALTH

Non-specific Effects of Vaccines

Vaccines may have effects other than against targeted diseases

Several hypotheses have been proposed:

- BCG and measles vaccines may reduce, and DT_wP vaccines may increase all-cause mortality in some populations and,
- that these effects may reflect the order in which vaccines are given.

Controversial as evidence available remains inconclusive

Long history of audit and review

Initially prompted by the studies of Peter Aaby in Guinea Bissau

2000

WHO consultants conduct research site audit Guinea Bissau. No definitive conclusions, additional data needed.

2001

WHO's Global Advisory Committee on Vaccine Safety (GACVS) finds no association between DTP and increased mortality.

2003-10

Several workshops and reviews (Danish National Research Foundation, GACVS) find conclusive evidence unlikely to be obtained from observational studies

SAGE asked the WG to determine

- if the current evidence on non-specific effects of BCG, DTP and measles containing vaccines on **all-cause mortality** in children **under 5 years** of age is sufficient to lead to adjustments in policy recommendations or to warrant further scientific investigation, and
- if so, to define the **path towards obtaining unequivocal evidence** on these issues that would support future robust, evidence-based adjustments in immunization policies, if warranted.

Working Group Membership

Terry Nolan (Australia, **SAGE**, Chair)

Christine Stabell Benn (Denmark)

Zulfiqar Bhutta (Pakistan/Canada, **SAGE**)

Mike Brennan (USA)

Stephen Evans (UK)

Paul Fine (UK)

Brad Gessner (France)

Dianne Griffin (USA)

Martin Mermikwu (Nigeria)

Kate O'Brien (USA, **SAGE**)

Walt Orenstein (USA)

Jaleela Sayed (Bahrain)

Dipika Sur (India)

WHO Commissioned Reviews

Immunologic human studies systematic overview

- **Andrew Pollard**, Rama Kandasamy, Merryn Voysey (all from Univ of Oxford)


Epidemiologic studies systematic overview

- **Julian Higgins** (Univ Bristol); Art Reingold (School of Public Health, UC Berkeley); Carla Soares (Israel)



1. Systematic Review of Non-Specific Immunological Effects of Vaccination

Andrew J Pollard, Rama Kandasamy, Merryn Voysey



Overview

- 77 studies
- 3 to 2345 study participants involved across the studies.
- 48% of studies utilised BCG
- 68% were exclusively conducted in a paediatric population.
- The final time-point of outcome measurement was primarily performed (70%) between one and 12 months after vaccination

Methodological Attributes

- Not one study was rated as having low risk of bias for all criteria.
- NSIEs do not feature as a primary outcome parameter in any of the RCTs.
- Only 55% of the included studies actually reported data in a usable format for this review.
- A diverse array of immunological assays were utilised in conjunction with differences in measurement parameters and statistical analysis.

Methodological Attributes

- Consistently low level of evidence
- Lack of any high quality (low risk of bias) randomised controlled trial with focussed primary endpoints designed around non-specific immunological outcomes.
- Datasets were not reported according to effect on sex

Confounder

N

Co-administration with Vitamin A?

Yes

3

No/Not reported

74

Presence of attribute that may affect response?


Yes

22

No

55

PHA stimulated responses to BCG vaccination



*Fold rise or ratios of medians or geometric means where published estimates are available

Conclusions

- Results inconclusive
- Heterogeneous data and inadequate high quality evidence to describe the non-specific immunological effects of current childhood vaccine programmes.
 - Data available not presented in a suitable fashion for particular analyses e.g. sex and Vitamin A
- Some evidence that in some study designs, with some vaccines, administered in some settings, where samples are taken at some time-points, and some in vitro assays are undertaken that NSIE may be detected in response to some in vitro stimuli but difficult to identify consistent findings

The Future

- Technology now makes it possible to make detailed, statistically robust, analysis of multiple parameters from small samples
 - Flow cytometry
 - Transcriptomics
 - Systems immunology
- Need high quality data on routine schedules with immunological endpoints
 - feasible and necessary to advance understanding of biology
- To address big picture questions need careful trial design and consensus about immunological endpoints (what, when)
 - Currently questionable feasibility but will be possible in the future

2. Systematic Review of Epidemiological Evidence

Julian Higgins, Karla Soares-Weiser, Arthur Reingold

http://www.who.int/immunization/sage/meetings/2014/april/4_SAGE_April_NSE_Higgins_Epidemiology.pdf?ua=1

Epidemiologic studies: systematic review objectives

- to review published and grey literature on epidemiological studies addressing “non-specific” effects of BCG, DTP and measles-containing vaccines on:
 - ~~i. mortality from causes other than the conditions that the vaccine is designed to prevent~~
 - ii. on **all-cause mortality** in children under five years of age.
- to appraise the evidence critically

Criteria for inclusion (PICO)

Participants: children up to 5 years

Intervention: vaccination (BCG, DTP or measles)

Comparators: no vaccination (BCG, DTP or measles respectively) or simultaneous administration of another vaccine

Outcome: mortality

Study designs: randomized (or quasi-randomized) controlled trials; cohort studies; case-control studies

Data sources: primary research papers; or re-analyses of primary studies with full articles describing methodology (published or unpublished, any language)

Identification

Records identified through database searching
N = 5,550

Additional records identified by contacting
experts in the field
N = 809

Screening

Records after duplicates removed
N = 5,600

Records screened
N = 5,600

Records excluded:
N = 4,723 (Databases)

Eligibility

Full-text articles scanned for eligibility
N = 852

Full-text articles excluded, with reasons
N = 639

Articles identified through reference lists: N = 13
Articles identified through the Working Group: N = 12


Full-text articles assessed for eligibility
N = 238

Full-text articles excluded, after
checking eligibility
N = 130. Reasons:
• Study design: N = 91
• No mortality: N = 51
• No data on ≤ 5 years: N = 14
• No data on vaccines: N = 37
• PDF not obtained: N = 6

Included

Full-text articles included (N = 73)

Locations of studies (73 articles)



Risk of bias assessment

- For RCTs: **Cochrane tool** for risk of bias in randomized trials
- Observational studies: In-development Cochrane tool for risk of bias in non-randomized studies
 - project led from University of Bristol
 - with international methodologists from (among others) universities of Harvard, Leiden, Liverpool, London School of Hygiene and Tropical Medicine, McGill, McMaster, Ottawa, Oxford, Paris Descartes, Toronto; and from RTI International, UK Medical Research Council, Nordic Cochrane Centre

Risk of bias is not the same as

Bias

- characteristics that raise risk of bias

Quality

- bias can occur in well-conducted studies

Imprecision

- reflected in the confidence interval

Reporting

- good methods may have been used but not well reported

Confounding: frailty and age


- **Frail children** believed less likely to be vaccinated
 - So those vaccinated inherently less likely to die
 - even if vaccine has no effect
 - Naive comparison of vaccinated vs not vaccinated likely to be **biased in favour of vaccine**
 - Lack of comprehensive adjustment for frailty
- **Confounding by age**
 - e.g. India 2006-2011 (excluded from analysis)
 - Can compute unadjusted comparison of DTP vs no DTP (i.e. BCG only), but children are at very different ages
 - **Confounding depends on mortality patterns over time**

Misclassification bias in determining non-vaccination

- e.g. Burkina-Faso (included in analysis)
- Researchers visited families every 6-12 months
- Collected information from vaccination cards
- Vaccinated: Vaccination recorded on vaccination card
- Unvaccinated: “When the card was not seen, we assumed that the child had not been vaccinated”
- It’s possible these children would have been vaccinated: if so the result is **biased towards no effect** (towards the null)

Other biases

- **Misclassification bias**
(survival bias)
 - Major problem can occur if vaccination status is updated retrospectively
 - particularly if vaccination cards are destroyed when a child dies
 - particularly if there is a long period between visits to the children
- Bias arising from **selection** of participants long after vaccines were given
 - A randomized trial would start follow-up at intervention
- **Co-interventions**
 - Vaccines are highly correlated so effect for BCG includes effects of DTP and measles vaccine



Results

1. BCG vs NO BCG

Studies

BCG and all-cause mortality

Results

Birth cohort

Age at first dose

Observation period

1. Randomized and quasi-randomized trials

Canada 1933-1945
 Guinea-Bissau 2002-2008 (early)
 Guinea-Bissau 2002-2008 (main)
 USA c.1935
 USA c.1941

10 days
 2 days
 2 days
 0-4 years
 7-10 days

age 60 months
 age 1 month
 age 1 month
 age 48 months
 age 60 months

2. Case-control studies

Benin 1983-1987

NR

age 4-36 months

3. Cohort studies

Guinea-Bissau 1984-1985
 Guinea-Bissau 1989-1999
 Guinea-Bissau 1990-1996
 India 1987-1989
 India 1998-2002
 Malawi 1995-1997
 Papua New Guinea 1989-1994
 Senegal 1996-1999

NR (0-8 months)
 1-7 days
 Median 1 month
 Median 1.6 months
 Median 19 days
 Median 16 days
 Median 1 month
 NR (by 12 months in 44%)


age 8 months
 age 6 months
 6 months follow-up
 age 12 months
 age 6 months
 age 8 months
 age 1-6 months
 age 24 months

Excluded (Very high risk of bias)

Bangladesh 1986-2001
 Burkina Faso 1985-1993
 Ghana 1998-2004
 India 2006-2011

0-2 months
 Mean 4.8 months
 NR (by 12 months in 57%)
 Mean 17 days

age 0-60 months
 6 months follow-up
 age 60 months
 age 1.2 months




Further details


Is there a difference in the effect of BCG by gender?

Analysis of boy/girl differences in effect
(‘statistical interaction’)

*Birth
cohort*

Burkina Faso 1985-1993
Guinea-Bissau 1989-1999
Guinea-Bissau 1990-1996
Guinea-Bissau 2002-2008 [RCT]
India 1998-2002
India 2006-2011
Malawi 1995-1997
Papua New Guinea 1989-1994
Senegal 1996-1999





Results

2. DTP vs NO DTP

DTP and all-cause mortality

- 16 independent birth cohorts of children, all observational (i.e. no RCTs)
 - 6 excluded from analysis due to very high risk of bias
- Always given with OPV where information available (8 out of 10 studies)
- Total sample size approximately 28,000 children
 - range 132 to 9,085
- Follow-up ranges from 6 to 36 months of age

DTP and all-cause mortality

1. Case-control studies

Benin 1983-1987

2. Cohort studies

Bangladesh 1986-2001

Burkina Faso 1985-1993

Guinea-Bissau 1984-1985

Guinea-Bissau 1990-1996

Guinea-Bissau 2002-2008

India 1998-2002

Malawi 1995-1997

Papua New Guinea 1989-1994

Senegal 1996-1999

Excluded (Very high risk of bias)

Ghana 1984-1991


Ghana 1998-2004

Guinea-Bissau 1989-1999

India 1987-1989

India 2006-2011


Philippines 1988-1991




Is there a difference in the effect of DTP by gender?

Analysis of boy/girl differences in effect
(‘statistical interaction’)

Bangladesh 1986-2001
Burkina Faso 1985-1993
Guinea-Bissau 1985-1985
Guinea-Bissau 1989-1999
Guinea-Bissau 1990-1996
Guinea-Bissau 2002-2008
India 1998-2002
India 2006-2011
Malawi 1995-1997
Papua New Guinea 1989-1994
Philippines 1988-1991
Senegal 1996-1999





Results

5. MEASLES VACCINE vs NO MEASLES VACCINE

Measles vaccine and all-cause mortality

- 28 independent birth cohorts
- 4 trials, 24 observational studies
 - 6 excluded from analysis due to very high risk of bias
- Total sample size approx. 116,000 children
 - range 99 to 36,650
- Follow up ranges from 9 to 60 months of age

Measles vaccine and all-cause mortality

1. Randomized trials

Guinea-Bissau 1989-1999
 Guinea-Bissau 1989-1999
 Guinea-Bissau 2002-2008
 Nigeria c.1961

2. Case-control studies

Benin 1983-1987
 India 1991-1998

3. Cohort studies

Bangladesh 1977-1985
 Bangladesh 1986-2001
 DR Congo 1973-1975
 Guinea-Bissau 1978-1983
 Guinea-Bissau 1978-1983
 Guinea-Bissau 1984-1985
 Guinea-Bissau 1990-1996
 Guinea-Bissau 1999-2002
 Haiti 1981-1982
 India 1986-1991
 India 1987-1989
 Malawi 1995-1997
 Papua New Guinea 1989-1994
 Senegal 1985-1987
 Senegal 1987-1989
 Senegal 1996-1999

Excluded (Very high risk of bias)

Burundi 1984-1988
 Ghana 1984-1991
 Ghana 1994-1999
 Ghana 1998-2004
 India 2006-2011
 Senegal 1989-1996

Age at first dose

6 months
 6 months
 4.5 months
 6-24 months

NR
 NR (before 12 months)

NR (from 9 months)
 NR (from 9 months)
 Mean 8.8 months
 NR (6-35 months)
 NR (6-35 months)
 Median 11.1; 15 months
 Median 10.6 months
 NR (by 12 mo in 55%)
 Median 9 months
 NR (at 6-8 [8-11] mo in 85% [15%])
 Median 9.4 months
 Median 10.8 months
 NR (by 12 months in 74%)
 Mean 15.8 months
 Mean 11.6 months
 NR (by 12 [24] mo in 9% [20%])

NR (at 9-11 months in 59%)
 NR (6-35 months)
 Median 9.1 months
 NR (by 12 [24] mo in 5% [64%])
 Mean 9.4 months
 Median 9.7 months


Observation period

age 6-9 months
 age 6-9 months
 age 4.5-9 months
 6-20 months follow-up

age 4-36 months
 age 12-60 months

age 9-60 months
 age 9-60 months
 age 7-21 months
 13 months follow-up
 12 months follow-up
 age 17.5 months or more
 age 7-19 months
 age 9-24 months
 age 9-39 months
 age 12-60 months
 age 12-60 months
 age 9-18 months
 age 6-11 months
 age 9-24 months
 age 9-24 months
 age 24 months


6 months follow-up
 4 months follow-up
 age 9-11 months
 age 60 months
 age 9-15 months
 age up to 24 months



Is there a difference in the effect of measles vaccine by gender?

Analysis of boy/girl differences in effect
(‘statistical interaction’)

- Ghana 1984-1991
- Guinea-Bissau 1984-1985
- Guinea-Bissau 1989-1999 [RCT]
- Guinea-Bissau 1999-2002
- Guinea-Bissau 2002-2008 [RCT]
- India 2006-2011
- Malawi 1995-1997
- Senegal 1985-1987
- Senegal 1987-1989
- Senegal 1989-1996
- Senegal 1996-1999



WG CONCLUSIONS

BCG: Data from randomized studies and observational studies are suggestive of a beneficial effect of BCG in reducing all-cause mortality within the first 6-12 months of life in countries with high childhood mortality. There is no evidence of a deleterious effect of BCG on all-cause mortality.

DTP: Mortality data related to DTP only from observational studies, and only when given in combination with other vaccines. These studies had significant methodological limitations. Because of these limitations, the overall effects of DTP vaccines under different epidemiological conditions remain unclear, in particular under circumstances where the target diseases have been reduced to very low levels. The Working Group concluded that the evidence does not support a change in policy for DTP.

MV: There was evidence that measles vaccine reduced the risk of all-cause mortality independent of its effect on confirmed measles mortality (an effect that appears to be stronger in girls than boys).

Working Group conclusions 2

Sub-questions

Each 3–5 studies, all observational, all judged at high risk of bias:

Results suggest ...

DTP+BCG vs BCG before DTP

... simultaneous administration may be associated with lower mortality (one study had 95% CIs that excluded no difference).

DTP before BCG compared with BCG before DTP

... no clear differences are apparent.

Co-administration of DTP and measles vaccine

... simultaneous administration may be associated with higher mortality.

Order of DTP and measles vaccine affect all-cause mortality:

... simultaneous administration may be associated with higher mortality.

Research Priorities

RANDOMIZED CONTROLLED TRIALS

- Need more **high quality randomised controlled trials**, wherever feasible. There are ethical and methodologic challenges.
- **RCTs of any DTP versus no DTP**, even with narrow time windows for outcome evaluation, and even in settings where endemic pertussis is low, may not be able to be conducted. The widespread use of pentavalent vaccine further complicates examination of NSEV.
- If RCTs were to be conducted, it may be appropriate to **aim for several large studies across a number of countries using the same protocol**.
- **RCTs of EPI schedule variants designed to minimise post-vaccination DTP person-time exposure before MCV vaccine** could be considered.

Research Agenda

OBSERVATIONAL STUDIES

- Further observational studies with inherent and substantial risk of bias would be **unlikely to provide conclusive evidence** about putative non-specific mortality effects.
- If observational studies are to be contemplated, their design and analysis should mimic what would be undertaken if it were to be a randomised controlled trial.
- Future studies should draw upon a **broad investigator pool and from a wide range of geographic locations and burden of disease settings**.
- The development of **standardized protocols** for both RCTs and observational studies of mortality effects, that address now well-recognised bias issues, should be considered.

Broad Research Agenda

- Any future studies should be designed and powered to **examine gender effects**. In addition, **immunological analysis should become a specific objective** of future studies based on formulating specific research questions that the study could answer.
- This could include assays that cover a breadth of immunological responses including antibodies, T-cell responses, cytokines, etc. However, the Working Group **argued against a shotgun approach** given that it would make interpretation of occasionally significant results among hundreds of comparisons difficult.
- **Systems biology approaches** may be particularly informative in providing a profile of host immune response.

SAGE determinations – April 2014

- Accepted WG conclusions and recommendations
- No change to existing policy for BCG, DTP and MV. Emphasized importance of strengthening delivery of all in EPI.
- Referred research agenda next steps to WHO's Immunization and Vaccine Related Implementation Research Advisory Committee (IVIR-AC)

Acknowledgements

- Oxford University: Andrew Pollard, Karlijn de Nie, Rama Kandasamy, Merryn Voysey, Fiona McQuaid, Rebecca Ryan, Olivia Orr, Ulrike Uhlig, Daniel O'Connor
- Julian Higgins, Professor of Evidence Synthesis, University of Bristol; Karla Soares-Weiser, Enhance Reviews Ltd; Art Reingold, Professor of Epidemiology, School of Public Health, UC Berkeley
- Ana Maria Henao Restrepo, Ximena Riveros Balta, WHO SAGE secretariat, Library staff.